PriceTargets.com logo

Nuformix - NFX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 293
  • Forecasted Upside: 298,879.59%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0.10 As of 03/21/2025 01:01 PM ET
▲ +0.005 (5.38%)

This chart shows the closing price for NFX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar0.10Closing price on 03/21/25:
Get New Nuformix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NFX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NFX

Analyst Price Target is GBX 293
▲ +298,879.59% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Nuformix in the last 3 months. The average price target is GBX 293, with a high forecast of GBX 293 and a low forecast of GBX 293. The average price target represents a 298,879.59% upside from the last price of GBX 0.10.

This chart shows the closing price for NFX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/260.0373147220293Closing price on 03/21/25: 0.10High293.00Average293.00Low293.00




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Nuformix.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/18/2025Canaccord Genuity GroupInitiated CoverageBuyGBX 293
(Data available from 3/22/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Nuformix logo
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Read More

Today's Range

Now: GBX 0.10
Low: 0.09
High: 0.11

50 Day Range

MA: GBX 0.08
Low: 0.05
High: 0.18

52 Week Range

Now: GBX 0.10
Low: 0.04
High: 0.30

Volume

73,348,922 shs

Average Volume

55,804,105 shs

Market Capitalization

£1.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuformix?

The following Wall Street sell-side analysts have issued research reports on Nuformix in the last year: Canaccord Genuity Group Inc..
View the latest analyst ratings for NFX.

What is the current price target for Nuformix?

0 Wall Street analysts have set twelve-month price targets for Nuformix in the last year. Their average twelve-month price target is GBX 293, suggesting a possible upside of 298,879.6%. Canaccord Genuity Group Inc. has the highest price target set, predicting NFX will reach GBX 293 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of GBX 293 for Nuformix in the next year.
View the latest price targets for NFX.

What is the current consensus analyst rating for Nuformix?

Nuformix currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NFX will outperform the market and that investors should add to their positions of Nuformix.
View the latest ratings for NFX.

What other companies compete with Nuformix?

Other companies that are similar to Nuformix include Evgen Pharma, Motif Bio, Destiny Pharma, Roquefort Therapeutics and ValiRx. Learn More about companies similar to Nuformix.

How do I contact Nuformix's investor relations team?

Nuformix's physical mailing address is Ste 31 Second Fl, 107 Cheapside, LONDON, EC2V 6DN, United Kingdom. The company's listed phone number is 44 1223 423 667. The official website for Nuformix is www.levrett.com. Learn More about contacing Nuformix investor relations.





Receive Nuformix News & Ratings Daily
Sign up to receive the latest news and ratings for Nuformix and its competitors with PriceTargets.com’s free daily newsletter.